Ionis Pharmaceuticals, Inc. (IONS) News
Follow Ionis Pharmaceuticals, Inc. (IONS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 72 public stories across 29 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Ionis Partner Roche Reports Sefaxersen Reduced Proteinuria 43.1% in Phase 3 IgAN Study
Roche’s Phase 3 study found investigational sefaxersen reduced proteinuria by 43.1% versus placebo at 37 weeks in adults with IgA nephropathy, Ionis reported.
EQUITY | Oct 23, 2026, 05:43 PM UTC
M
FDA Approves GSK’s HIBSAGO; Phase 3 Data Show 19% Functional Cure Rate
Ionis Pharmaceuticals said its partner GSK received U.S. FDA approval for HIBSAGO (bepirovirsen). The Phase 3 B-Well trials showed a 19% functional cure rate.
REGULATION | Oct 21, 2026, 08:24 PM UTC
M
FDA Approves GSK’s Hibsago for Chronic Hepatitis B Treatment
GSK announced that the FDA approved Hibsago (bepirovirsen) for chronic hepatitis B treatment in the U.S.
REGULATION | Oct 21, 2026, 01:20 AM UTC
M
Ionis Says EU Committee Recommends Expanded Tryngolza Approval
Ionis Pharmaceuticals said the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended expanded approval of Tryngolza for people with severe hypertriglyceridemia.
REGULATION | Oct 16, 2026, 11:13 AM UTC
L
Weekly Recap: Ulefnersen Phase 3 win in FUS-ALS and Sefaxersen UPCR hit
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) rallied after reporting positive Phase 3 FUSION topline results for ulefnersen and a 37—week interim win in Roche—linked IMAgINATION for sefaxersen in IgAN, with safety consisten
NEWS | Sep 28, 2026, 11:06 AM UTC
L
Ionis Pharmaceuticals Price Target Maintained With a $100.00/Share by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 11:09 AM UTC
L
Ionis reports positive Phase 3 interim results for sefaxersen in IgA nephropathy
Ionis reported positive prespecified interim Phase 3 results for sefaxersen showing significant proteinuria reduction versus placebo at 37 weeks.Key Highlights:Original SEC Filing: IONIS PHARMACEUTICALS INC [ IONS ] - 8-
REGULATION | Sep 23, 2026, 10:15 AM UTC
L
Ionis Pharmaceuticals, Inc. (IONS) Phase 3 IgAN Study Meets Interim Primary Endpoint
Ionis reported that partner Roche’s Phase 3 IMAgINATION study of sefaxersen in IgA nephropathy met its prespecified interim primary endpoint, showing statistically significant and clinically meaningful proteinuria reduct
NEWS | Sep 23, 2026, 05:00 AM UTC
L
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner Roche today announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary I
NEWS | Sep 23, 2026, 05:00 AM UTC
M
Otsuka and Ionis experimental ALS drug meets late-stage goal
Otsuka Pharmaceutical and Ionis Pharmaceuticals said their experimental drug met the main goal in a late-stage study in patients with a rare inherited form of amyotrophic lateral sclerosis.
EQUITY | Sep 22, 2026, 12:36 PM UTC
M
ARK Invest adds Meta, Ionis and other biotech firms
Cathie Wood’s ARK Invest added Meta Platforms (META) and biotech names Ionis Pharmaceuticals (IONS), Veracyte (VCYT), Scribe Therapeutics (SCTX) and Beam Therapeutics (BEAM), while trimming 10x Genomics (TXG).
EQUITY | Sep 22, 2026, 11:10 AM UTC
L
Ionis Pharmaceuticals Price Target Cut to $80.00/Share From $89.00 by Guggenheim
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 01:31 PM UTC
H
Notable healthcare headlines for the week: UnitedHealth, Amgen, and CooperCompanies in focus
Wall Street rallied on Friday after the latest consumer inflation report came in broadly in line with expectations, helping ease concerns over price pressures and supporting a rebound across risk assets.On Friday, the Do
NEWS | Sep 13, 2026, 01:11 PM UTC
H
Chip stocks lead Nasdaq's weekly gains; Amgen plunges after trial setback
The Nasdaq Composite Index NYSE:COMP climbed on Friday alongside major Wall Street indexes after the latest consumer inflation report came in largely in line with expectations. It closed +0.96% higher after jumping by ov
NEWS | Sep 11, 2026, 08:31 PM UTC
L
IONS: Strong FDA approvals and robust launches drive growth, with pipeline and market leadership advancing
Multiple FDA approvals and strong launch momentum for new therapies highlight a year of strategic success. Key programs in sHTG, HAE, and HBV are advancing, while competitive positioning and pipeline innovation remain pr
REGULATION | Sep 10, 2026, 02:51 PM UTC
L
Novartis facing board change threat from shareholder following trial failures
A large Novartis NYSE:NVS shareholder is calling for changes on the Swiss pharma giant's board in the aftermath of two phase 3 drug trial setbacks in the last few weeks.Artisan Partners Managing Director David Samra told
MNA | Sep 10, 2026, 02:33 PM UTC
L
IONS: Strategic approvals and strong launches drive growth, with pipeline poised for further milestones
Multiple FDA approvals and strong product launches mark a year of strategic success, with TRYNGALZA and DAWNZERA gaining rapid traction and robust sales outlooks. Pipeline advances include siRNA programs and anticipated
REGULATION | Sep 10, 2026, 01:46 PM UTC
L
Barclays cuts Ionis Pharmaceuticals price target to $85 from $90
Barclays cut its price target on Ionis Pharmaceuticals to $85.00 per share from $90.00, according to Benzinga’s ratings actions via TradingView News.
EQUITY | Sep 09, 2026, 01:22 PM UTC
L
Morgan Stanley cuts Ionis price target to $104 from $110
Morgan Stanley cut its price target on Ionis Pharmaceuticals to $104.00 per share from $110.00, according to Benzinga ratings actions via TradingView News.
EQUITY | Sep 08, 2026, 06:14 PM UTC
L
Goldman Sachs maintains neutral on Ionis Pharmaceuticals
Goldman Sachs maintains a neutral rating on Ionis Pharmaceuticals.
EQUITY | Sep 08, 2026, 02:27 PM UTC
L
Ionis Pharmaceuticals maintained at Market Perform by BMO
Ionis Pharmaceuticals was maintained at Market Perform by BMO Capital, according to TradingView News.
EQUITY | Sep 08, 2026, 12:34 PM UTC
L
Ionis (IONS) price target cut to $85 by Canaccord Genuity
Canaccord Genuity cut its Ionis Pharmaceuticals price target to $85.00 per share from $95.00, while maintaining a Buy rating, according to TradingView News via Benzinga.
EQUITY | Sep 08, 2026, 12:05 PM UTC
L
HC Wainwright cuts Ionis Pharma price target to $100
HC Wainwright & Co. lowered its Ionis Pharmaceuticals price target to $100.00 a share from $115.00, while maintaining a Buy rating, according to TradingView News via Benzinga.
EQUITY | Sep 08, 2026, 11:28 AM UTC
M
Novartis shares slide after-hours after heart-trial fails to cut events
Novartis shares sank after-hours after a heart-disease trial failed to show that lowering an inherited risk factor prevented heart attacks and strokes. NVS closed at $159.99, then slipped as much as about 7% after hours.
EQUITY | Sep 04, 2026, 10:52 PM UTC
M
Ionis and Novartis heart drug fails late-stage main goal
Ionis Pharmaceuticals and partner Novartis said their experimental drug aimed at lowering high levels of a fat-and-protein particle in heart patients missed the main goal in a late-stage trial.
EQUITY | Sep 04, 2026, 09:19 PM UTC
M
Novartis announces pelacarsen Lp(a)HORIZON Phase 3 topline: primary endpoint missed
Novartis announced pelacarsen Phase 3 Lp(a)HORIZON topline results. The study did not meet its primary endpoint to reduce the risk of cardiovascular events, a composite including cardiovascular death and non-fatal myo…
EQUITY | Sep 04, 2026, 08:41 PM UTC
H
FDA approves ZANVASTRO for Alexander disease, expanding access
FDA approved ZANVASTRO as the first disease-modifying therapy for Alexander disease, with a broad label for children and adults. Approval was based on clinical data showing motor function benefit and favorable safety.
REGULATION | Sep 04, 2026, 04:31 PM UTC
M
Ionis wins FDA approval for zanvastro targeting rare brain disease
Ionis Pharmaceuticals received regulatory approval for zanvastro (Zilganersen) to treat a rare brain disease in both adult and pediatric patients. The news is getting a muted market reaction.
REGULATION | Sep 04, 2026, 04:13 PM UTC
L
Needham maintains $86 price target on Ionis Pharmaceuticals
Needham maintained a $86.00/share price target for Ionis Pharmaceuticals.
EQUITY | Sep 04, 2026, 04:09 PM UTC
M
FDA approves ZANVASTRO for Alexander disease, broad access label
ZANVASTRO received early FDA approval as the first disease-modifying therapy for Alexander disease, with a broad label for children and adults. The pivotal trial reported motor function stabilization and a favorable safe
REGULATION | Sep 04, 2026, 03:26 PM UTC
L
BMO Capital raises Ionis Pharmaceuticals price target to $61
BMO Capital raised its price target on Ionis Pharmaceuticals to $61.00 per share from $60.00 and maintained its Market Perform rating.
EQUITY | Sep 04, 2026, 03:24 PM UTC
H
FDA approves ZANVASTRO as first disease-modifying therapy for Alexander disease
ZANVASTRO (zilganersen) is now FDA-approved as the first disease-modifying therapy for Alexander disease in both children and adults, citing pivotal trial data showing motor function stabilization and a favorable safety
REGULATION | Sep 04, 2026, 01:49 PM UTC
L
HC Wainwright & Co. maintains Ionis $115 price target
HC Wainwright & Co. maintained its $115.00-per-share price target for Ionis Pharmaceuticals, according to Benzinga/TradingView News.
EQUITY | Sep 04, 2026, 10:17 AM UTC
H
Ionis says FDA approves ZANVASTRO for Alexander disease
Ionis said the FDA approved ZANVASTRO (zilganersen) as the first disease-modifying treatment for Alexander disease.
REGULATION | Sep 04, 2026, 10:13 AM UTC
M
Ionis (IONS) shares rise after-hours after FDA approval for Zanvastro
Ionis Pharmaceuticals shares edged up 1% after-hours Thursday after the FDA approved Zanvastro as the first treatment for Alexander disease, ahead of a stated deadline. Shares fell about 6% in regular trading after Ultra
REGULATION | Sep 03, 2026, 09:19 PM UTC
M
US FDA approves Ionis therapy Zanvastro for rare brain disorder
The U.S. FDA approved Ionis Pharmaceuticals’ zilganersen (Zanvastro) to treat a rare genetic disorder affecting the brain’s white matter, with use for adults and pediatric patients.
REGULATION | Sep 03, 2026, 08:27 PM UTC
L
Ionis management to hold fireside chats at investor conferences
Ionis Pharmaceuticals said management will participate in fireside chats at upcoming investor conferences. The company also said the presentations will be available via a live webcast on its Investors & Media section.
EQUITY | Sep 03, 2026, 11:05 AM UTC
L
Canaccord reiterates Buy on IONS, keeps $95 price target
Canaccord reiterates a Buy rating on IONS and keeps a $95 price target, citing a number of underappreciated value drivers.
EQUITY | Aug 24, 2026, 11:55 AM UTC
M
Ionis to present new sHTG data at ESC Congress 2026
Ionis says it will present new data on severe hypertriglyceridemia management at the European Society of Cardiology Congress 2026.
EQUITY | Aug 20, 2026, 11:07 AM UTC
L
BMO initiates IONS at Market Perform, $60 target
BMO assigns IONS a Market Perform rating with a $60 price target, with no catalyst supplied in the alert.
EQUITY | Aug 19, 2026, 11:50 AM UTC
M
IONS PT Raised to $76 by JP Morgan
IONS price target increased
EQUITY | Aug 03, 2026, 09:59 AM UTC
M
Insiders Buy HDSN, XAIR, ARTV, IONS Shares
Insiders purchase shares of four companies
EQUITY | Aug 03, 2026, 09:28 AM UTC
H
Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks
Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY ) stock plunged on Thursday after the company lowered its fiscal 2026 guidance. The company reported second-quarter adjusted earnings of $1.84 per share, beating the consensus o
EARNINGS | Jul 30, 2026, 06:37 PM UTC
M
IONS Maintains Overweight
IONS maintains overweight rating
EQUITY | Jul 30, 2026, 11:16 AM UTC
H
Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio
Biogen Inc. (NASDAQ: BIIB ) stock is trading higher on Wednesday after the company reported second-quarter adjusted earnings of $3.60 per share, beating the consensus of $2.96. Revenue Tops Expectations On Growth Across
EARNINGS | Jul 29, 2026, 05:36 PM UTC
L
Ionis Pharmaceuticals Affirms FY2026 Sales Guidance of $875.000M-$900.000M vs $895.148M Est
Ionis Pharmaceuticals (NASDAQ: IONS ) affirms FY2026 sales outlook from $875.000 million-$900.000 million to $875.000 million-$900.000 million vs $895.148 million estimate.
EARNINGS | Jul 29, 2026, 11:08 AM UTC
L
IONS Ionis Pharmaceuticals RESULTS: Q2, Q2 Net Income $115M, Q2 ADJ Operating Income $-57M vs. EST $-178.4M, Q2 Operating Income $-102M, Q2
IONS Ionis Pharmaceuticals RESULTS: Q2, Q2 Net Income $115M, Q2 ADJ Operating Income $-57M vs. EST $-178.4M, Q2 Operating Income $-102M, Q2 operating expenses $370M, Ionis Pharmaceuticals Earnings Notes:, - Ionis Pharmac
EARNINGS | Jul 29, 2026, 11:03 AM UTC
H
Implied EPS movers for tomorrow AM: PG +/-3.4%, APH +/-11.5%, VRT +/-11.2%, ADP +/-5.0%, FLEX +/-20.8%, SOFI +/-8.5%, BSX +/-7.1%, HUM +/-7.
Implied EPS movers for tomorrow AM: PG +/-3.4%, APH +/-11.5%, VRT +/-11.2%, ADP +/-5.0%, FLEX +/-20.8%, SOFI +/-8.5%, BSX +/-7.1%, HUM +/-7.8%, GD +/-3.7%, TEVA +/-6.5%, JCI +/-7.8%, CTSH +/-11.7%, ODFL +/-8.3%, ETR +/-4
EARNINGS | Jul 28, 2026, 06:05 PM UTC
L
IONS Earnings pre-market tomorrow: qtr EPS est ($1.07) (high ($0.84)/low ($1.23)), 30-day avg EPS revision -3% (7 analyst(s) revised up, 4 d
IONS Earnings pre-market tomorrow: qtr EPS est ($1.07) (high ($0.84)/low ($1.23)), 30-day avg EPS revision -3% (7 analyst(s) revised up, 4 down), qtr revs est $190.67Mm; FY EPS est ($3.64), FY revs est $895.15Mm; short i
EARNINGS | Jul 28, 2026, 04:12 PM UTC
L
IONS Competitor ARWR data meets the Bar in SHTG @ GSCO
IONS Competitor ARWR data meets the Bar in SHTG @ GSCO
EQUITY | Jul 23, 2026, 12:21 PM UTC
L
IONS large market that's still underappreciated @ BARC
IONS large market that's still underappreciated @ BARC
EQUITY | Jul 23, 2026, 11:35 AM UTC
L
IONS Downgrade from Outperform to Peerperform at Wolfe Research
IONS Downgrade from Outperform to Peerperform at Wolfe Research
EQUITY | Jul 16, 2026, 11:54 AM UTC
L
IONS downgraded from Outperform to Peer Perform @ Wolfe
IONS downgraded from Outperform to Peer Perform @ Wolfe
EQUITY | Jul 16, 2026, 11:27 AM UTC
H
Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says
() -- Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Frida
EARNINGS | Jul 10, 2026, 05:01 PM UTC
L
H.C. Wainwright trims Ionis price target, says trial failure reaction 'overdone'
H.C. Wainwright trims Ionis price target, says trial failure reaction 'overdone'
EQUITY | Jul 10, 2026, 01:20 PM UTC
H
Ionis Pharmaceuticals Reaffirms Fiscal 2026 Financial Guidance
() -- Ionis Pharmaceuticals (IONS) reaffirmed its fiscal 2026 financial guidance, leaving unchanged the outlook issued with its first-quarter results, citing a regulatory filing on Friday. Copyright © 2026. All rights re
EARNINGS | Jul 10, 2026, 10:51 AM UTC
H
Ionis Pharmaceuticals Affirms FY2026 Sales Guidance of $875.000M-$900.000M vs $893.928M Est
Ionis Pharmaceuticals (NASDAQ: IONS ) affirms FY2026 sales outlook from $875.000 million-$900.000 million to $875.000 million-$900.000 million vs $893.928 million estimate.
EARNINGS | Jul 10, 2026, 10:14 AM UTC
L
Ionis Pharmaceuticals Insider Sold Shares Worth $1,744,623, According to a Recent SEC Filing
() -- C Frank Bennett, Executive Vice President, Chief Scientific Officer, on July 07, 2026, sold 20,536 shares in Ionis Pharmaceuticals (IONS) for $1,744,623. Following the Form 4 filing with the SEC, Bennett has contro
GEOPOLITICS | Jul 10, 2026, 08:01 AM UTC
H
Top Midday Decliners
() -- Aimei Health Technology (AFJK) terminated its merger deal with United Hydrogen Group, effective immediately, as the companies failed to complete the transaction within the agreed timeframe, according to a statement
MNA | Jul 09, 2026, 06:17 PM UTC
H
Top Midday Stories: Tensions Rise as US, Iran Trade Attacks; Micron to Invest $3 Billion in US Semiconductor Supply Chain
() -- All three major US stock indexes were up in late-morning trading Thursday, as investors monitored the re-escalation of hostilities between the US and Iran in the Middle East. Iran struck US military infrastructure
MACRO | Jul 09, 2026, 03:33 PM UTC